Craig Paterson
Net worth: 404 340 $ as of 31/05/2024
Profile
Presently, Craig Paterson is Chief Medical Officer at Allakos, Inc. In the past he was Chief Medical Officer at Endo International Plc and Senior VP-Medical & Clinical Development at Salix Pharmaceuticals Ltd. He received a graduate degree from McMaster University and an MBA from the University of Tennessee.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
ALLAKOS, INC.
0.37% | 04/12/2023 | 323,472 ( 0.37% ) | 404 340 $ | 31/05/2024 |
Former positions of Craig Paterson
Companies | Position | End |
---|---|---|
ALLAKOS INC. | Chief Tech/Sci/R&D Officer | 09/02/2024 |
UMass Chan Medical School | Corporate Officer/Principal | - |
Vivelix Pharmaceuticalsc Corp. | Founder | - |
ENDO INTERNATIONAL PLC | Chief Tech/Sci/R&D Officer | - |
SALIX PHARMACEUTICALS, LTD. | Corporate Officer/Principal | - |
Training of Craig Paterson
McMaster University | Graduate Degree |
University of Tennessee | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ALLAKOS INC. | Health Technology |
Private companies | 3 |
---|---|
Salix Pharmaceuticals Ltd.
Salix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Salix Pharmaceuticals Ltd. develops and commercializes prescription drugs and medical devices used in the treatment of gastrointestinal diseases, endocrinology, hepatology, colorectal surgery, and internal medicine. It offers Anusol, Apriso, Colazal, Deflux, Diuril, Fenoglide, MoviPrep, Pepcid, Solesta, and Zegerid. The company was founded by randy W. Hamilton and Lorin K. Johnson in1989 and is headquartered in Bridgewater, NJ. | Health Technology |
Endo International Plc
Endo International Plc Pharmaceuticals: MajorHealth Technology Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland. | Health Technology |
Vivelix Pharmaceuticalsc Corp. |
- Stock Market
- Insiders
- Craig Paterson